The effects of vitamin D intake and status on symptom severity and quality-of-life in adults with irritable bowel syndrome (IBS): a systematic review and meta-analysis
Open Access
- 5 September 2024
- journal article
- research article
- Published by Taylor & Francis in Critical Reviews in Food Science and Nutrition
- Vol. 65 (25) , 4994-5007
Abstract
Many individuals with irritable bowel syndrome (IBS) have insufficient or deficient serum 25-hydroxyvitamin D [25(OH)D] status; however, it is not clear if improved vitamin D nutritional status through higher intake can improve symptom severity and quality of life. This systematic review and meta-analysis aimed to identify if changes in vitamin D intake or status affect symptom severity and quality of life in adults with IBS.Data Sources: MEDLINE®, Cochrane Central Register of Controlled Trials, Global Health, EMBASE, and Web-of-Science databases were systematically searched for relevant articles to August 12, 2024, in the English language.Study Selection: Clinical trials, prospective observational studies, and Mendelian randomization (MR) analyses reporting the effect of vitamin D intake or status on IBS-related outcomes were included.Data Extraction and Synthesis: Article review and data extraction were conducted by 2 authors following the PRISMA guidelines. Random effects meta-analyses and the Nutrition Quality Evaluation Strengthening Tools to assess risk of bias were employed for randomized controlled trials.Main Outcome(s) and Measure(s): Primary outcomes included measures of serum 25(OH)D status, symptom severity, and quality of life. 12 studies from 15 articles were included (n = 7 RCTs; n = 3 single-arm interventions; n = 2 MR). Seven study populations had deficient (n = 5; Pooled mean difference [95% CI]: 20.33 [12.91, 27.74] ng/mL; I2 = 97.9%). Quality of life scores improved significantly in deficient populations (n = 3; 3.19 [2.14, 4.24]; I2 = 0.0%). Non-significant decreased trends in IBS symptom severity were shown across populations (n = 6: -25.89 [-55.26, 3.48]; I2 = 92.8%). Moderate level evidence indicate vitamin D supplementation may improve status in adults with IBS and quality of life in those with deficient status at baseline.Keywords
Funding Information
- Nestlé Health Science U.S.
This publication has 47 references indexed in Scilit:
- Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021Gastroenterology, 2022
- NUQUEST—NUtrition QUality Evaluation Strengthening Tools: development of tools for the evaluation of risk of bias in nutrition studiesThe American Journal of Clinical Nutrition, 2021
- Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trialEuropean Journal of Nutrition, 2021
- Vitamin D supplementation: upper limit for safety revisited?Aging Clinical and Experimental Research, 2020
- 25-Hydroxyvitamin D assay standardisation and vitamin D guidelines paralysisPublic Health Nutrition, 2020
- Soy isoflavones and cholecalciferol reduce inflammation, and gut permeability, without any effect on antioxidant capacity in irritable bowel syndrome: A randomized clinical trialClinical Nutrition ESPEN, 2019
- Adverse events from large dose vitamin D supplementation taken for one year or longerThe Journal of Steroid Biochemistry and Molecular Biology, 2019
- Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2018
- GRADE guidelines: A new series of articles in the Journal of Clinical EpidemiologyJournal of Clinical Epidemiology, 2011
- Implementation of SI units for clinical laboratory data: style specifications and conversion tablesThe Journal of Nutritional Biochemistry, 1990